Pharmaceutical Regulatory Authorities – News & Updates (2026)

Every month we check 4 pharmaceutical industry regulatory bodies (the FDA, European Commission, MHRA, and HPRA) and bring together their news into one handy update.

This round‑up is written for people who work in, or are retraining into, pharmaceutical and medical device manufacturing and need to understand the highly regulated environment they’ll be working in.

Rather than visiting each regulator’s website separately, you can use this page to quickly scan what’s changed and then click through to the original announcements to read more detail.

Clicking on any of the links below will take you directly to the regulator’s own website where you can read the related story.

TL;DR – Key Pharma Regulatory Updates

• Regulators covered: This round‑up summarises updates from the FDA, European Commission, MHRA and HPRA, with direct links so you can read each announcement on the regulator’s own website.
• Who it’s for: People working in, or retraining into the pharmaceutical and medical device manufacturing industry, especially in manufacturing, QA, validation/CQV/C&Q, engineering and CSV roles.
• Why it matters: These updates highlight changes that can impact GMP requirements, documentation, inspections, data integrity and validation activities, all of which affect how you do your job day‑to‑day.
• Career impact: Understanding how regulatory authorities think and how their guidance is evolving helps you stand out to hiring managers, support your company during inspections and build a stronger case for promotion or career change into pharma.
• Next step: Use this summary to stay informed each month, then build deeper job‑ready knowledge and skills.

• 1 May – FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
  
• 6 May – FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
• 6 May – FDA Expands AI Capabilities and Completes Data Platform Consolidation
• 8 May – FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
• 8 May – FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
• 11 May – FDA Advances Drug Repurposing to Address Unmet Medical Needs
• 22 May – FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
• 29 May – FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs

• 12 May – Commission welcomes political agreement on Critical Medicines Act
• 18 May – Medical Devices: New Implementing Regulation sets out uniform requirements for conformity assessment and notified bodies
• 27 May – Commission publishes analysis underpinning the Biotech Act proposals

• 1 May – MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease
• 7 May – MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
• 11 May – MHRA invites views on proposed changes to medical device regulation
• 11 May – MHRA opens UK-wide consultation on redefining gene therapies
• 11 May – MHRA strengthens safety warnings for finasteride and dutasteride
• 13 May – MHRA supports Northern Ireland life sciences sector with new hub
• 15 May – MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa
• 21 May – MHRA consults on new regulatory framework to make UK a global leader in rare disease therapy development
• 28 May – Precautionary recall of blood pressure medication (Crescent Pharma Limited Ramipril 2.5mg capsules) after packaging error
• 29 May – Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient

• The HPRA published no new press announcements in May 2026. You can monitor HPRA news directly at hpra.ie/news-events/news.

Frequently Asked Questions About Pharma Regulatory Updates & Careers

Q1) How do I keep up with pharmaceutical regulatory changes?

The most reliable way is to follow updates directly from the main regulatory authorities – such as the FDA, European Commission, MHRA and HPRA – and to sign up for their email alerts or RSS feeds. However, that can be time‑consuming if you are working shifts or juggling family commitments.

That’s why we publish a monthly round‑up of the most relevant news from these regulators, with direct links to the original announcements, so you can quickly see what has changed and decide what you need to read in more detail.

Likewise, for a comprehensive plain-English guide to GMP covering all 12 principles, 18 factory floor rules, and how regulatory inspections work, see our Good Manufacturing Practices guide.

Q2) Which regulatory authorities oversee pharmaceutical manufacturing?

The main authorities covered in this article are:

• The Food and Drug Administration (FDA)
• The European Commission
• The Medicines and Healthcare products Regulatory Agency (MHRA)
• The Health Products Regulatory Authority (HPRA)

Depending on where you work, you may also need to be aware of other national or regional regulators, but these bodies cover a large proportion of global pharmaceutical manufacturing activity.

Q3) Do I need a science degree to work in pharmaceutical manufacturing?

No. Many people working in pharmaceutical manufacturing do not have a science degree. There are excellent career opportunities for everyone. What employers look for is:

1. A solid understanding of how a GMP‑regulated environment works, a commitment to quality and safety, and the right technical skills – all of which can be developed through targeted online retraining programmes.
2. People who can put the Patient at the heart of everything they do, people who can demonstrate that they understand Patient Safety and Product Quality.

Q4) How can I retrain for a job in pharmaceutical manufacturing?

Most people follow a two‑step path:

1. Build a foundation of industry‑specific knowledge, such as GMP, pharmaceutical manufacturing processes and regulatory expectations etc.
2. Gain job‑ready skills for a specific role, such as QA, CQV/C&Q, CSV or manufacturing operations.

GetReskilled offers structured online retraining courses and programmes designed specifically for adults changing career into pharma or medical device manufacturing. You can study part‑time around your current job, with guidance from experienced lecturers and industry professionals.

Q5) What skills do I need for QA, validation or CSV roles in pharma?

While each role is different, employers typically look for:

• A strong understanding of GMP, quality systems and regulatory requirements
• Excellent documentation, attention to detail and problem‑solving skills
• The ability to work effectively in cross‑functional teams
• For CSV roles, a good grasp of computerised systems, data integrity and risk‑based validation

Q6) How These Updates Affect Your Work in Pharma

Working in pharmaceutical or medical device manufacturing means working in a constantly changing regulatory environment. Updates like the ones listed above can influence:

• How manufacturing processes are controlled, documented and monitored
• The types of checks and records your QA and quality systems must maintain
• The focus of inspections and audits carried out by regulators
• The expectations around validation, CQV/C&Q and CSV activities

Employers value people who can follow regulatory news and understand how it might affect day‑to‑day operations in a GMP environment. If you’re changing career into pharma, this kind of awareness shows that you understand the seriousness of working in a regulated industry. If you’re already in the sector, staying up‑to‑date can support your case for promotion or progression.

Q7) What is the difference between the FDA, MHRA, HPRA and the European Commission?

Each of these bodies regulates pharmaceutical and medical device manufacturing in a different geographic region. The FDA (Food and Drug Administration) is the US regulator — but because many medicines sold in the US are manufactured in Ireland and elsewhere, the FDA regularly inspects Irish and European manufacturing sites. The European Commission sets pharmaceutical legislation and grants marketing authorisations for medicines across the EU, through the European Medicines Agency (EMA). The MHRA (Medicines and Healthcare products Regulatory Agency) is the UK regulator. The HPRA (Health Products Regulatory Authority) is Ireland’s national regulator, responsible for authorising and monitoring medicines, medical devices, and clinical trials within Ireland. In practice, a pharmaceutical manufacturing site in Ireland may be subject to inspection and oversight from more than one of these bodies simultaneously.

Q8) Does the HPRA regulate medical devices as well as medicines in Ireland?

Yes. The HPRA regulates both medicines and medical devices in Ireland. On the medicines side, it authorises, monitors, and enforces standards for human and veterinary medicines manufactured or sold in Ireland. On the medical devices side, it acts as a competent authority under EU medical device regulations, overseeing the safety and performance of devices on the Irish market and conducting vigilance activities when device-related incidents are reported. This dual role is important for people retraining into the industry to understand — Ireland’s manufacturing sector covers both pharma and medtech, and the regulatory environment for each, while overlapping in some areas, has distinct requirements.

Q9) How often do pharmaceutical regulatory authorities publish updates?

All four regulators covered in this round-up publish updates continuously throughout the month rather than on a fixed schedule. The FDA tends to be the most active, publishing press announcements multiple times per week covering new drug approvals, guidance documents, safety communications, and enforcement actions. The European Commission typically publishes less frequently but with significant impact when it does — major marketing authorisations and legislative changes tend to come in batches. The MHRA publishes several updates per week covering approvals, safety alerts, and regulatory guidance. The HPRA publishes less frequently than the other three, with updates typically covering product recalls, safety alerts, and national licensing decisions. GetReskilled compiles the most relevant updates from all four into this monthly round-up so you don’t need to monitor each website separately.

Q10) What happens when a pharmaceutical company fails a regulatory inspection?

The consequences depend on the severity of the findings. Regulators classify observations from inspections into categories — the FDA uses terms like Voluntary Action Indicated (VAI), Official Action Indicated (OAI), and issues Warning Letters for serious violations. The MHRA and HPRA use similar tiered systems. In less serious cases, the company is required to submit a corrective action plan and demonstrate it has addressed the issues identified. In more serious cases, the regulator can restrict or suspend manufacturing activities, issue a public warning, or in extreme cases pursue legal action. For people working in pharmaceutical manufacturing, this is why GMP compliance is treated with such seriousness day-to-day — a single documentation error or procedural deviation can be picked up in an inspection and, if systemic, can have significant consequences for the site and everyone who works there.

Q11) How do regulatory changes affect people working on the pharmaceutical manufacturing floor?

Regulatory changes can affect day-to-day work in pharmaceutical manufacturing in several direct ways. A new FDA guidance document on data integrity, for example, may require a site to update how electronic records are managed and how operators log entries in batch records. A new EU regulation on serialisation may require changes to packaging lines and the training that goes with them. A precautionary recall — like several of the MHRA announcements in this round-up — triggers a detailed investigation on the manufacturing side to identify the root cause of the issue and implement corrective actions. For people in QA, validation, CQV and CSV roles, regulatory changes are particularly impactful because they often directly affect the standards that must be met for a process, system or piece of equipment to be considered validated. Staying aware of regulatory developments is therefore not just a career interest — for many roles in pharma, it is a core part of the job.

European Commission – https://health.ec.europa.eu/medicinal-products/latest-updates_en

FDA – https://www.fda.gov/news-events/fda-newsroom/press-announcements

HPRA – https://www.hpra.ie/news-events/news

MHRA – https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency